USP7 and cancer: Therefore, accumulated studies have suggested that USP7 is a promising target for cancer therapy [10, 13] and thus several small-molecule compounds, such as HBX 41,108 [14], and P5091 [15], has been developed to inhibit the enzymatic activity of USP7 and showed promising antitumor functions in various cancer models.